Detectable mutations by NGS in patients with low-grade gliomas included V600E (N = 2), BRAF KIAA-1549 (N = 3) EGFR (N = 1), PDGFR (N = 1) and Gli 1 (N = 1). Patients receiving a targeted agent for high-grade tumors all experienced progressive disease. This evidence concerns the gene BRAF and central nervous system cancer.